Drugs / KB304
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06724900 | Nov 2024 → Jul 2025 overdue | Pseudoatrophoderma colli, skin pigmentation disorder | Krystal Biotech, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB304 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06724900 ↗ |